Materials and methods
This study was conducted from July 2021 to January 2022 in the hospitals in Jordan. The study population consisted of 6132 who received different types of vaccine against COVID-19 as in the following
Total: Number of patients= 6132 divided to
(Group1: Patients with one dose: 2017) divided to (1317 received one dose Sinopharm + 320 received one dose Pfizer vaccine + 380 received one dose AstraZeneca)
(Group2: Patients with two doses: 4115) divided to 1317 received two doses Sinopharm + 1006 received two doses Pfizer + 1792 received two dose AstraZeneca
Results:
Table 1. for the total number
| Patients with one dose (2017) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 273 (13.53%) | 214 (10.61%) | 372 (18.44%) | 412 (20.42%) | 14 (0.69%) | 507 (25.13%) | 14 (0.69%) | 161 (7.98%) | 50 (2.48%) |
| Patients with two doses (4115) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 114 (2.77%) | 1033 (25.1%) | 328 (7.97%) | 411 (9.99%) | 232 (5.64%) | 1739 (42.26%) | 7 (0.175) | 247 (6%) | 4 (0.1%) |
Table 2. received one dose for each type of vaccine
| Patients with one dose Sinopharm (1317) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 178 (13.51%) | 139 (10.55%) | 243 (18.45%) | 269 (20.425%) | 9 (0.68%) | 331 (25.132%) | 9 (0.683%) | 105 (7.97%) | 33 (2.5%) |
| Patients with one dose Pfizer (320) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 44 (13.75%) | 34 (10.629%) | 59 (18.43%) | 65(20.31%) | 2 (0.625%) | 81(25.31%) | 2 (0.625%) | 26 (8.125%) | 7 (2.187%) |
| Patients with one dose AstraZeneca (380) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 51(13.42%) | 41 (10.79%) | 70 (18.42%) | 78 (20.5%) | 3 (0.79%) | 95 (25%) | 3 (0.789%) | 30 (7.89%) | 10 (2.63%) |
Table 2. received two doses for each type of vaccine
| Patients with two doses Sinopharm (1317) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 36 (2.7 %) | 331 (25%) | 105 (7.79%_ | 132 (10.02%) | 74 (5.618%) | 557 (42.29%) | 2 (0.1518%) | 79 (5.99%) | 1 (0.076%) |
| Patients with two doses Pfizer (1006) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 28 (2.783%) | 252 (25.05%) | 80 (7.95%) | 100 (9.94%) | 56 (5.56%) | 424(42.147%) | 2 (0.198%) | 60 (5.96%) | 1 (0.1%) |
| Patients with two dose AstraZeneca (1792) | ||||||||
| Cardiovascular diseases | Respiratory diseases | Diabetes | ||||||
| Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization | Death | Infected without hospitalization | Infected with hospitalization |
| 50 (2.79%) | 449 (25.05%) | 143 (7.98%) | 179 (9.98%) | 101 (5.636%) | 757 (42.24%) | 3 (0.167%) | 108 (6.026%) | 2 (0.111%) |
Discussion:
Please write a strong discussion and comparing between different vaccine…..etc.
Do you need help with this assignment or any other? We got you! Place your order and leave the rest to our experts.